Altimmune ( (ALT) ) has released its Q4 earnings. Here is a breakdown of the information Altimmune presented to its investors.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics, particularly in the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH).
In its latest earnings report, Altimmune highlighted significant progress in its clinical trials, particularly the Phase 2b IMPACT trial for pemvidutide in MASH, with top-line data expected in the second quarter of 2025. The company also announced FDA clearance for investigational new drug applications in two additional indications, with Phase 2 trials set to begin mid-2025.
Financially, Altimmune reported cash and short-term investments totaling $131.9 million as of December 31, 2024. The company experienced an increase in research and development expenses, primarily due to ongoing development activities for pemvidutide. Despite a net loss of $23.2 million for the fourth quarter, this was an improvement from the previous year’s loss, reflecting strategic cost management and a focus on core projects.
Altimmune’s strategic initiatives include strengthening its board with industry veterans and planning a virtual R&D Day to discuss pemvidutide’s development. These steps underscore the company’s commitment to advancing its pipeline and exploring new therapeutic avenues.
Looking ahead, Altimmune remains optimistic about its clinical programs and anticipates further progress in its trials and regulatory engagements, aiming to solidify its position in the biopharmaceutical landscape.